USE OF IVERMECTIN IN COVID-19
Author(s): Sarvesh Ravi Kandoi, Pramita Gharde*, Ashok Mehendale
The emergence of Coronavirus infection has produced a concerning scenario all across the world. COVID-19 is made up of a single stranded positive sense RNA gene that is wrapped in a crown shaped collection of spike glycoproteins in an external membrane. Depending on the person's genetics, race, age and geographic region, COVID-19 infection can cause a range of symptoms and morbidity. Pulmonary epithelial cell death, thrombosis, hyper coagulation and vascular leak are all part of COVID-19 pathophysiology, which can lead to sepsis in severe instances. As a result of these events, Acute Respiratory Distress Syndrome (ARDS) and lung ???ros?s occur. The vital to create a therapeutic approach is to stop COVID-19 from spreading. COVID-19 instances are on the rise every day, yet there is no effective therapy or vaccine available. Several clinical studies are being done in COVID-19 to assess the effectiveness of various drugs and vaccinations. To yet, no one medication has been discovered to be successful for Coronavirus patients. This analysis examines the proof for using ivermectin, an anti-parasitic drug with antiviral properties. Ivermectin, an FDA approved medicine which is used to treat parasitic infection, was lately discovered to have a suppressive impact on Coronavirus. It possesses antiviral activity in vitro and in vivo against a number of viruses, in addition to anti-parasitic capabilities. As a result of this antiviral effect, it has been ?dent???ed as a potential COVID treatment drug. In vitro, ivermectin was been demonstrated to be inhibitory to RNA and DNA viruses. The goal of this theoretical article is to assess the available information on COVID-19 transcription features and to explain the method of action of ivermectin, which may justify its therapeutic use in COVID-19 treatment.